Dow Jones
39.387,76 +331,37 (+0,85%) Nasdaq
16.346,26 +43,51 (+0,27%) Nikkei 225
38.073,98 -128,39 (-0,34%) EUR/USD
1,0786 +0,0035 (+0,32%) Bitcoin EUR
57.906,64 +513,56 (+0,89%) CMC Crypto 200
1.344,18 +44,08 (+3,39%)
Surrozen, Inc. (SRZNW)
| Chiusura precedente | 0,0290 |
| Aperto | 0,0290 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,0290 - 0,0290 |
| Intervallo di 52 settimane | 0,0290 - 0,0290 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,88 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,6950 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSurrozen Provides Second Quarter 2023 Financial Results
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company
- GlobeNewswire
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while improving neurologic scoreResults highlight potential of selective Fzd4 Wnt antibody for central nervous system disorders involving an abnormal blood-brain-barrier SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics t
